NasdaqCM:CELCBiotechs
Assessing Celcuity (CELC) Valuation As Investor Optimism And Conflicting Fair Value Views Intensify
Why Celcuity (CELC) is on investors’ radar
Celcuity (CELC), a clinical stage oncology company licensing its lead drug candidate Gedatolisib from Pfizer, is drawing attention as investors reassess the stock after recent share price moves.
See our latest analysis for Celcuity.
At a share price of $132.88, Celcuity’s 1 month share price return of 5.75% and 3 month share price return of 22.7% sit alongside a very large 1 year total shareholder return. This suggests that momentum has been building...